Click Therapeutics is acquiring the assets of Better Therapeutics two months after that digital therapeutics developer announced it would lay off all employees and shut down. Better’s main asset is AspyreRx, an FDA-authorized mobile app for type 2 diabetes.
The post With M&A Deal, Click Therapeutics’ Digital Prospects in Metabolic Disease Get Better appeared first on MedCity News.
Recent Posts
Categories
Related Articles
These 3 Mindset Shifts Will Help Providers Deliver Consumer-Driven Care, Investor Says
One of the most important things providers can do on the journey...
Top Hospitals for Pacemaker Implantation Surgery in India: What you need to know?
Pacemaker implantation is a life-saving procedure for people with irregular heart rhythms....
Links
When is a public health problem a crisis? LA has the worst...
Remembering Thomas E. Kurtz
By MIKE MAGEE This has been a challenging week for me, but...
Leave a comment